The type 1 insulin-like growth factor receptor signalling system and targeted tyrosine kinase inhibition in cancer

Journal of International Medical Research

Volumn 41, Issue 2, 2013, Pages 253-264

  Haisa, Minoru ^a  

^a Okayama Citizens Hospital   (Japan)

Author keywords

Cancer; Igf1; Igf1r; Tyrosine kinase inhibitor

Indexed keywords

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; 4 AMINO 5 (3 BENZYLOXYPHENYL) 7 [3 (1 PYRROLIDINYLMETHYL)CYCLOBUTYL] 7H PYRROLO[2,3 D]PYRIMIDINE; ADENOSINE TRIPHOSPHATASE; ANTINEOPLASTIC AGENT; BMS 536924; BMS 554417; BVP 51004; FLUINDOSTATIN; INSULIN RECEPTOR; LINSITINIB; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NORDIHYDROGUAIARETIC ACID; NVP AEW 541; PROTEIN TYROSINE KINASE; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; XL 228;

ANTINEOPLASTIC ACTIVITY; BINDING SITE; BREAST CANCER; CELL CYCLE PROGRESSION; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG TOLERABILITY; ENZYME INHIBITION; EWING SARCOMA; GASTROINTESTINAL STROMAL TUMOR; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MESOTHELIOMA; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL TUMOR; NEUROBLASTOMA; NONHUMAN; PANCREAS CANCER; PROSTATE CANCER; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; PROTEIN TRANSPORT; REVIEW; SIGNAL TRANSDUCTION; SYNOVIAL SARCOMA; TUMOR GROWTH;

EID: 84878376748     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060513476585     Document Type: Review

References (92)

1. Cross M and Dexter TM. Growth factors in development, transformation, and tumorigenesis. Cell 1991; 64: 271-280.
2. Ullrich A, Gray A, Tam AW, et al. Insulinlike growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that deEne functional speciEcity. EMBO J 1986; 5: 2503-2512.
3. Belfiore A. The role of insulin receptor isoforms and hybrid insulin/IGF-I receptors in human cancer. Curr Pharm Des 2007; 13: 671-686.
4. Heidegger I, Pircher A, Klocker H, et al. Targeting the insulin-like growth factor network in cancer therapy. Cancer Biol Ther 2011; 11: 701-707.
5. Hofmann F and García-Echeverría C. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov Today 2005; 10: 1041-1047.
6. Arnaldez FI and Helman LJ. Targeting the insulin growth factor receptor 1. Hematol Oncol Clin North Am 2012; 26: 527-542.
7. Ewing GP and Goff LW. The insulin-like growth factor signaling pathway as a target for treatment of colorectal carcinoma. Clin Colorectal Cancer 2010; 9: 219-223.
8. Takeuchi K and Ito F. Receptor tyrosine kinases and targeted cancer therapeutics. Biol Pharm Bull 2011; 34: 1774-1180.
9. LeRoith D, Werner H, Beitner-Johnson D, et al. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995; 16: 143-163.
10. Adams TE, Epa VC, Garrett TP, et al. Structure and function of the type 1 insulinlike growth factor receptor. Cell Mol Life Sci 2000; 57: 1050-1093.
11. Massagué J and Czech MP. The subunit structures of two distinct receptors for insulin-like growth factors I and II and their relationship to the insulin receptor. J Biol Chem 1982; 257: 5038-5045.
12. Werner H and LeRoith D. The role of the insulin-like growth factor system in human cancer. Adv Cancer Res 1996; 68: 183-223.
13. Carlberg M, Dricu A, Blegen H, et al. Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin- like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth. J Biol Chem 1996; 271: 17453-17462.
14. Favelyukis S, Till JH, Hubbard SR, et al. Structure and autoregulation of the insulinlike growth factor 1 receptor kinase. Nat Struct Biol 2001; 8: 1058-1063.
15. Browner WS, Kahn AJ, Ziv E, et al. The genetics of human longevity. Am J Med 2004; 117: 851-860.
16. Munshi S, Hall DL, Kornienko M, et al. Structure of apo, unactivated insulin-like growth factor-1 receptor kinase at 1.5 A resolution. Acta Crystallogr D Biol Crystallogr 2003; 59: 1725-1730.
17. Moxham CP, Duronio V and Jacobs S. Insulin-like growth factor I receptor β-subunit heterogeneity. Evidence for hybrid tetramers composed of insulin-like growth factor I and insulin receptor heterodimers. J Biol Chem 1989; 264: 13238-13244.
18. Soos MA and Siddle K. Immunological relationships between receptors for insulin and insulin-like growth factor I. Evidence for structural heterogeneity of insulin-like growth factor I receptors involving hybrids with insulin receptors. Biochem J 1989; 263: 553-563.
19. Treadway JL, Morrison BD, GoldEne ID, et al. Assembly of insulin/insulin-like growth factor-1 hybrid receptors in vitro. J Biol Chem 1989; 264: 21450-21453.
20. Pandini G, Frasca F, Mineo R, et al. Insulin/ insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 2002; 277: 39684-39695.
21. Pandini G, Vigneri R, Costantino A, et al. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res 1999; 5: 1935-1944.
22. Vincent AM and Feldman EL. Control of cell survival by IGF signaling pathways. Growth Horm IGF Res 2002; 12: 193-197.
23. Chen YW, Boyartchuk V and Lewis BC. Differential roles of insulin-like growth factor receptor- and insulin receptormediated signaling in the phenotypes of hepatocellular carcinoma cells. Neoplasia 2009; 11: 835-845.
24. Gauguin L, Klaproth B, Sajid W, et al. Structural basis for the lower affinity of the insulin-like growth factors for the insulin receptor. J Biol Chem 2008; 283: 2604-2613.
25. Fürstenberger G and Senn HJ. Insulin-like growth factors and cancer. Lancet Oncol 2002; 3: 298-302.
26. Danielsen A, Larsen E and Gammeltoft S. Chromaffin cells express two types of insulin- like growth factor receptors. Brain Res 1990; 518: 95-100.
27. Bennett A, Wilson DM, Liu F, et al. Levels of insulin-like growth factors I and II in human cord blood. J Clin Endocrinol Metab 1983; 57: 609-612.
28. Kalus W, Zweckstetter M, Renner C, et al. Structure of the IGF-binding domain of the insulin-like growth factor-binding protein-5 (IGFBP-5): implications for IGF and IGF-I receptor interactions. EMBO J 1998; 17: 6558-6572.
29. Firth SM and Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002; 23: 824-854.
30. Sitar T, Popowicz GM, Siwanowicz I, et al. Structural basis for the inhibition of insulinlike growth factors by insulin-like growth factor-binding proteins. Proc Natl Acad Sci USA 2006; 103: 13028-13033.
31. Jerome L, Alami N, Belanger S, et al. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2- overexpressing breast tumors and potentiates Herceptin activity in vivo. Cancer Res 2006; 66: 7245-7252.
32. So AI, Levitt RJ, Eigl B, et al. Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. Clin Cancer Res 2008; 14: 6944-6954.
33. Mehrian-Shai R, Chen CD, Shi T, et al. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci U S A 2007; 104: 5563-5568.
34. Levitt RJ, Georgescu MM and Pollak M. PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2. Biochem Biophys Res Commun 2005; 336: 1056-1061.
35. Perks CM and Holly JM. IGF binding proteins (IGFBPs) and regulation of breast cancer biology. J Mammary Gland Biol Neoplasia 2008; 13: 455-469.
36. Li R, Pourpak A and Morris S. Inhibition of the Insulin-like Growth Factor-1 Receptor (IGF1R) Tyrosine Kinase as a Novel Cancer Therapy Approach J Med Chem. 2009 52: 4981-5004.
37. Shelton JG, Steelman LS, White ER and McCubrey JA. Synergy between PI3K/Akt and Raf/MEK/ERK pathways in IGF-1R mediated cell cycle progression and prevention of apoptosis in hematopoietic cells. Cell Cycle 2004; 3: 372-379.
38. Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-1101.
39. Jacinto E, Facchinetti V, Liu D, et al. SIN1/ MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006; 127: 125-137.
40. Perrini S, Laviola L, Carreira MC, et al. The GH/IGF1 axis and signaling pathways in the muscle and bone: mechanisms underlying age-related skeletal muscle wasting and osteoporosis. J Endocrinol 2010; 205: 201-210.
41. Chen D, Water SB, Holt KH, et al. SOS phosphorylation and disassociation of the Grb2-SOS complex by the ERK and JNK signaling pathways. J Biol Chem 1996; 271: 6328-6332.
42. Buchwalter G, Gross C and Wasylyk B. Ets ternary complex transcription factors. Gene 2004; 324: 1-14.
43. Mittelstadt PR, Salvador JM, Fornace AJ Jr, et al. Activating p38 MAPK: new tricks for an old kinase. Cell Cycle 2005; 4: 1189-1192.
44. Sunami T, Byrne N, Diehl RE, et al. Structural basis of human p70 ribosomal S6 kinase-1 regulation by activation loop phosphorylation. J Biol Chem 2010; 285: 4587-4594.
45. Tognon CE and Sorensen PH. Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy. Expert Opin Ther Targets 2012; 16: 33-48.
46. Mahmoudabady M, Mathieu M, Touihri K, et al. Cardiac insulin-like growth factor-1 and cyclins gene expression in canine models of ischemic or overpacing cardiomyopathy. BMC Cardiovasc Disord 2009; 9: 49.
47. Samani A, Yakar S, LeRoith D, et al. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007; 28: 20-47.
48. Liu JP, Baker J, Perkins AS, et al. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993; 75: 59-72.
49. Laustsen PG, Russell SJ, Cui L, et al. Essential role of insulin and insulin-like growth factor 1 receptor signaling in cardiac development and function. Mol Cell Biol 2007; 27: 1649-1664.
50. Nakae J, Kido Y and Accili D. Distinct and overlapping functions of insulin and IGF-I receptors. Endocr Rev 2001; 22: 818-835.
51. Russo VC, Gluckman PD, Feldman EL, et al. The insulin-like growth factor system and its pleiotropic functions in brain. Endocr Rev 2005; 26: 916-943.
52. Romano G. The complex biology of the receptor for the insulin-like growth factor-1. Drug News Perspect 2003; 16: 525-531.
53. Pandini G, Genua M, Frasca F, et al. Sex steroids upregulate the IGF-1R in prostate cancer cells through a nongenotropic pathway. Ann N Y Acad Sci 2009; 1155: 263-267.
54. Tamimi RM, Colditz GA, Wang Y, et al. Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer. Breast Cancer Res Treat 2011; 128: 243-250.
55. Shan HB, Zhang R, Li Y, et al. Expression of IGF-1R in colorectal polyps and its role in colorectal carcinogenesis. Technol Cancer Res Treat 2011; 10: 381-389.
56. Nair PN, De Armond DT, Adamo ML, et al. Aberrant expression and activation of insulin- like growth factor-1 receptor (IGF-1R) are mediated by an induction of IGF-1R promoter activity and stabilization of IGF- 1R mRNA and contributes to growth factor independence and increased survival of the pancreatic cancer cell line MIA PaCa-2. Oncogene 2001; 20: 8203-8214.
57. Al-Jamal RT and Kivelä T. Prognostic associations of insulin-like growth factor-1 receptor in primary uveal melanoma. Can J Ophthalmol 2011; 46: 471-476.
58. Meissner T, Seckinger A, Rème T, et al. Gene expression profiling in multiple myeloma - reporting of entities, risk, and targets in clinical routine. Clin Cancer Res 2011; 17: 7240-7247.
59. Kalra N, Zhang J, Yu Y, et al. Efficacy of anti-insulin-like growth factor I receptor monoclonal antibody cixutumumab in mesothelioma is highly correlated with insulin growth factor-I receptor sites/cell. Int J Cancer 2012; 131: 2143-2152.
60. Bielen A, Perryman L, Box GM, et al. Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/β. Mol Cancer Ther 2011; 10: 1407-1418.
61. Sachdev D, Singh R, Fujita-Yamaguchi Y, et al. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for antiinsulin- like growth factor therapy in breast cancer. Cancer Res 2006; 66: 2391-2402.
62. Schernhammer ES, Holly JM, Hunter DJ, et al. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Relat Cancer 2006; 13: 583-592.
63. Valentinis B and Baserga R. IGF-I receptor signalling in transformation and differentiation. Mol Pathol 2001; 54: 133-137.
64. Baserga R, Peruzzi F and Reiss K. The IGF- 1 receptor in cancer biology. Int J Cancer 2003; 107: 873-877.
65. Friedrichs N, Küchler J, Endl E, et al. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma. J Pathol 2008; 216: 428-439.
66. Sachdev D, Hartell JS, Lee AV, et al. A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J Biol Chem 2004; 279: 5017-5024.
67. Reinmuth N, Fan F, Liu W, et al. Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest 2002; 82: 1377-1389.
68. Lee JS, Weiss J, Martin JL, et al. Increased expression of the mannose 6-phosphate/ insulin-like growth factor-II receptor in breast cancer cells alters tumorigenic properties in vitro and in vivo. Int J Cancer 2003; 107: 564-570.
69. Zhang X and Yee D. Insulin-like growth factor binding protein-1 (IGFBP-1) inhibits breast cancer cell motility. Cancer Res 2002; 62: 4369-4375.
70. Chen W, Feng Y, Zhao Q, et al. Human monoclonal antibodies targeting nonoverlapping epitopes on insulin-like growth factor II as a novel type of candidate cancer therapeutics. Mol Cancer Ther 2012; 11: 1400-1410.
71. Goya M, Miyamoto S, Nagai K, et al. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligandspecific antibody to human insulin-like growth factors. Cancer Res 2004; 64: 6252-6258.
72. Rodon J, DeSantos V, Ferry RJ Jr, et al. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther 2008; 7: 2575-2588.
73. Yin S, Girnita A, Strömberg T, et al. Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma. Neuro Oncol 2010; 12: 19-27.
74. Arora A and Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005; 315: 971-979.
75. Pollak M. Insulin, insulin-like growth factors and neoplasia. Best Pract Res Clin Endocrinol Metab 2008; 22: 625-638.
76. Höpfner M, Baradari V, Huether A, et al. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. Endocr Relat Cancer 2006; 13: 135-149.
77. Slomiany MG, Black LA, Kibbey MM, et al. Insulin-like growth factor-1 receptor and ligand targeting in head and neck squamous cell carcinoma. Cancer Lett 2007; 248: 269-279.
78. García-Echeverría C, Pearson MA, Marti A, et al. In vivo antitumor activity of NVPAEW541 - a novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004; 5: 231-239.
79. Scotlandi K, Manara MC, Nicoletti G, et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVPAEW541 in musculoskeletal tumors. Cancer Res 2005; 65: 3868-3876.
80. Höpfner M, Huether A, Sutter AP, et al. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. Biochem Pharmacol 2006; 71: 1435-1448.
81. Whitson BA, Jacobson BA, Frizelle S, et al. Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma. Thoracic Surgery Directors Association Resident Research Award. Ann Thorac Surg 2006; 82: 996-1002.
82. Höpfner M, Sutter AP, Huether A, et al. Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer. World J Gastroenterol 2006; 12: 5635-5643.
83. Tanno B, Mancini C, Vitali R, et al. Downregulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo. Clin Cancer Res 2006; 12: 6772-6780.
84. Manara MC, Landuzzi L, Nanni P, et al. Preclinical in vivo study of new insulin-like growth factor-I receptor-specific inhibitor in Ewing's sarcoma. Clin Cancer Res 2007; 13: 1322-1330.
85. Maiso P, Ocio EM, Garayoa M, et al. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells. Br J Haematol 2008; 141: 470-482.
86. Moser C, Schachtschneider P, Lang SA, et al. Inhibition of insulin-like growth factor- I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis. Eur J Cancer 2008; 44: 1577-1586.
87. Tarn C, Rink L, Merkel E, et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci USA 2008; 105: 8387-8392.
88. Piao W, Wang Y, Adachi Y, et al. Insulinlike growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas. Mol Cancer Ther 2008; 7: 1483-1493.
89. Lisztwan J, Pornon A, Chen B, et al. The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer. Breast Cancer Res 2008; 10: R56.
90. Girnita A, Girnita L, Del Prete F, et al. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 2004; 64: 236-242.
91. Vasilcanu D, Girnita A, Girnita L, et al. The cyclolignan PPP induces activation loopspecific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway. Oncogene 2004; 23: 7854-7862.
92. Ji QS, Mulvihill MJ, Rosenfeld-Franklin M, et al. A novel, potent, and selective insulinlike growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor-dependent tumor growth in vivo. Mol Cancer Ther 2007; 6: 2158-2167.